Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylnaltrexone + codeine is a combination of two drugs with opposing actions on opioid receptors. Methylnaltrexone is a peripherally acting μ-opioid receptor antagonist, primarily used to treat opioid-induced constipation by blocking the effects of opioids like codeine in the gastrointestinal tract without affecting their pain-relieving properties in the central nervous system[1][3][4][5][6]. Codeine is an opioid analgesic that acts as an agonist at μ-opioid receptors to provide pain relief. When used together, this combination could theoretically allow for effective pain management with reduced risk of opioid-induced constipation, though such combinations are not standard clinical practice and may be considered investigational or off-label.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylnaltrexone + codeine.